News & Events

Salarius Targeting Key Safety and Efficacy Data Milestones in 2020 HOUSTON, Oct. 8, 2019 -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting...

Salarius Pharmaceuticals Announces Senior Leadership Changes Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer HOUSTON, Sept. 13, 2019 -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX),...

Salarius’ lead program, Seclidemstat, is in a Phase 1 clinical trial for Ewing sarcoma, a rare and devastating pediatric bone and soft-tissue cancer; Early cohort...

Comprehensive pre-clinical study will test first-in-class investigational therapy Seclidemstat   PHOENIX, AZ / HOUSTON, TX – August 26, 2019 - The Ivy Brain Tumor Center...